2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2698 Pursuing credible normalcy: A constructivist grounded theory of socially negotiated illness cognitions in hemophilia

Roy Khalife, MD, MHPE, Lindsay Cowley, MA2, Kori A LaDonna, PhD3
1 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, University of Ottawa, Ottawa, Ontario, Canada
2 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3 University of Ottawa, Ottawa, Ontario, Canada

Background:

Advances in hemophilia treatment have reduced bleeding and disability, yet people with hemophilia may continue to encounter disbelief, delayed care, and uncertainty when diagnostic labels, lived experiences, and others’ perceptions do not align. We examined how adults with hemophilia construct and negotiate illness cognitions and how these cognitions shape their everyday and healthcare experiences.

 

Methods:

We conducted a constructivist grounded theory study involving adults with inherited hemophilia in Canada. Participants were purposively recruited locally and through the national patient organization to capture variation in sex, age, diagnosis, and severity. We conducted semi-structured interviews informed by Leventhal’s Common-Sense Model of illness representations. Interviews were audio-recorded, transcribed verbatim, and analyzed iteratively using initial, focused, and theoretical coding, constant comparison, memoing, and reflexive team discussion.

 

Results:

Twenty-nine adults participated: 22 male and 7 female; 22 had hemophilia A and 7 hemophilia B; 11 had severe, 5 moderate, and 13 mild hemophilia. Participants sought to live ordinary lives while ensuring that hemophilia became recognizable and believable when clinically or socially consequential, such that their diagnosis, symptoms, experiential knowledge, and requests for treatment or accommodation would be accepted and acted upon without repeated proof or exaggerated displays of illness.

We conceptualized this provisional alignment of biomedical labels, embodied experience, and social recognition as credible normalcy: a state in which hemophilia could remain in the background of everyday life while becoming sufficiently legible when symptoms, risks, expertise, or care needs required recognition and action. Achieving and restoring credible normalcy required legitimacy work: the conversational, cognitive, emotional, and practical labor used to establish the credibility of symptoms, experiential knowledge, diagnosis, and requests for care.

Legitimacy work occurred through four interrelated processes: (1) aligning diagnostic labels with lived experience, such as identifying as having “mild hemophilia” rather than as a “carrier” when seeking care; (2) asserting illness legitimacy in clinical spaces through treatment cards, factor levels, hemophilia-specific knowledge, or contact with the hemophilia treatment center; (3) interpreting the present through generational and therapeutic lenses by comparing contemporary treatment with family experiences of joint damage, limited factor access, or transfusion-transmitted infection; and (4) calibrating everyday risk to sustain ordinary participation by carrying treatment, locating treatment centers before travel, and preparing employers, schools, or coaches to respond appropriately. When these efforts succeeded, hemophilia receded into the background. When labels, bodily experiences, or others’ responses became misaligned, legitimacy work intensified. Repeated failures contributed to advocacy fatigue, delayed or avoided care, and identity renegotiation.

Conclusion:

Illness cognitions in hemophilia are socially negotiated and repeatedly tested across clinical and everyday settings. Care should therefore address not only bleeding control but also the credibility burden placed on patients. Clinicians and systems can reduce this burden by recognizing experiential expertise, avoiding overreliance on severity labels or outward appearance, and providing individualized plans that support timely care. Because this purposively recruited Canadian sample had universal access to hemophilia therapies, transferability to less-engaged patients, other healthcare systems, and contexts requires further study. Future research should examine how legitimacy work influences care-seeking, treatment decisions, adherence, and outcomes, and test interventions that reduce repeated demands for credibility. This framework may also apply to other rare hematologic disorders with episodic or invisible symptoms, limited clinician familiarity, and reliance on patient expertise.

Roy Khalife, MD, MHPE: Bayer - Honoraria; Roche - Honoraria; Pfizer - Honoraria; Medecins Francophones du Canada - Honoraria; Sanofi - Honoraria; Novo Nordisk - Honoraria; Sobi - Honoraria; Novartis - Honoraria; Canadian Drug Agency - Honoraria; Takeda - Honoraria; CSL Behring - Honoraria; Octapharma - Honoraria